Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
Metrics: PDF 2049 views | ?
Present: The current funding information is incomplete.
Corrected: The complete funding information is given below.
Original article: Oncotarget. 2017; 8:15943-51. DOI:https://doi.org/10.18632/oncotarget.13056.
This study was supported partly by Astra Zeneca Korea Ltd. This study was supported in part by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C1440, B. C. Cho), a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI13C1948 to H.R. Kim) and a faculty research grant of Yonsei University College of Medicine for 2012(6-2012-0134, B.C. Cho.).
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.